# EDGAR Filing Document

**Accession Number:** 0001656536
**File Stem:** 0000950170-23-007382
**Filing Date:** 2023-3
**Character Count:** 5269
**Document Hash:** b4df73dfc1df7e3bda86e367e6113867
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-007382.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0000950170-23-007382

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230310

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230310

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Decibel Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001656536
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 464198709
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40030
- **FILM NUMBER:** 23725100

**BUSINESS ADDRESS:**
- **STREET 1:** 1325 BOYLSTON STREET
- **STREET 2:** SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** 617-370-8701

**MAIL ADDRESS:**
- **STREET 1:** 1325 BOYLSTON STREET
- **STREET 2:** SUITE 500
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215

?xml version="1.0" encoding="ASCII"? 8-K

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

------

**FORM** 8-K

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of report (Date of earliest event reported):** March 10, 2023

------

Decibel Therapeutics, Inc.

**(Exact Name of Registrant as Specified in Charter)** 

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40030 | 46-4198709 |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission**<br>**File Number)** | **(IRS Employer**<br>**Identification No.)** |
| 1325 Boylston Street**,** Suite 500<br>Boston**,** Massachusetts | 1325 Boylston Street**,** Suite 500<br>Boston**,** Massachusetts | 02215 |
| **(Address of Principal Executive Offices)** | **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code:** (617) 370-8701

**Not applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

------

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange**<br>**on which registered** |
| Common stock, $0.001 par value per share | DBTX | Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

Decibel Therapeutics, Inc. (the "Company") is aware of media reports indicating the closure of Silicon Valley Bank ("SVB") and the appointment of the Federal Deposit Insurance Corporation as receiver. The Company announced that, as of March 10, 2023, the Company had three cash deposit accounts at SVB, each with a balance less than or equal to $250,000. The Company also announced that, as of March 10, 2023, it had approximately $4.0 million in a money market account at a separate independent financial institution for which SVB acts solely as custodian. The Company's other cash resources are held in custody accounts at a separate independent financial institution. The Company plans to continue to monitor the situation with SVB.

The information in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | DECIBEL THERAPEUTICS, INC. | DECIBEL THERAPEUTICS, INC. |
| Date: March 10, 2023 | By: | /s/ Laurence Reid |
|  |  | Name: Laurence Reid, Ph.D. |
|  |  | Title: President and Chief Executive Officer |

---

------